Bioxcel Therapeutics Inc (BTAI)

$1.90 -0.12 (-5.94%)
Market Cap 12.23M
Revenue (ttm) 2.27M
Net Income (ttm) -59.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,625.55%
Debt to Equity Ratio -1.17
Volume 1,404,300
Avg Vol 350,654
Day's Range N/A - N/A
Shares Out 6.06M
Stochastic %K 20%
Beta 0.04
Analysts Sell
Price Target $8.33

Company Profile

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally...

Industry: Biotechnology
Sector: Healthcare
Phone: 475 238 6837
Address:
555 Long Wharf Drive, 12th Floor, New Haven, United States
Hurtadogoalkeeper
Hurtadogoalkeeper Jul. 16 at 8:26 AM
$BTAI https://www.gurufocus.com/news/2978384/btai-bioxcel-therapeutics-receives-steady-buy-rating-from-lucid-capital-markets-btai-stock-news
0 · Reply
Bulltrader988
Bulltrader988 Jul. 16 at 7:19 AM
$BTAI 👃👀 https://www.tipranks.com/news/the-fly/bioxcel-therapeutics-announces-patent-allowance-for-dexmedetomidine-thefly?utm_source=webullapp.com&utm_medium=referral
0 · Reply
Bulltrader988
Bulltrader988 Jul. 16 at 7:19 AM
$BTAI 👃👀 https://www.tipranks.com/news/the-fly/lucid-reiterates-buy-on-bioxcel-after-patent-application-approval-thefly?utm_source=webullapp.com&utm_medium=referral
0 · Reply
NancyBraddy886
NancyBraddy886 Jul. 16 at 5:43 AM
$BTAI Avoiding setups that move too fast
0 · Reply
Thabeastdavis
Thabeastdavis Jul. 15 at 7:20 PM
$BTAI how does this get a $66 price target and it falls??
1 · Reply
Ernesto62
Ernesto62 Jul. 15 at 7:12 PM
$BTAI yep
0 · Reply
jv39
jv39 Jul. 15 at 6:21 PM
$BTAI Fuck this shit
1 · Reply
sn0wball
sn0wball Jul. 15 at 4:27 PM
$BTAI they also say nucana is worth 54$
0 · Reply
_www_larval_com_
_www_larval_com_ Jul. 15 at 4:02 PM
$BTAI has turned -4% lower to 3% (~866Kv) in the last few minutes, 08/15 options, follow for more volatility.
0 · Reply
RJLeonii
RJLeonii Jul. 15 at 2:56 PM
$BTAI PT of $66 🤑
1 · Reply
Latest News on BTAI
BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Jul 1, 2025, 7:00 AM EDT - 15 days ago

BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

May 27, 2025, 8:01 AM EDT - 7 weeks ago

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement

May 27, 2025, 7:00 AM EDT - 7 weeks ago

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 7:00 AM EDT - 2 months ago

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

Mar 27, 2025, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 11, 2025, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 7, 2025, 7:00 AM EST - 4 months ago

BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

Mar 4, 2025, 4:15 PM EST - 4 months ago

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

BioXcel Therapeutics Announces $14 Million Registered Direct Offering

Mar 3, 2025, 3:33 PM EST - 4 months ago

BioXcel Therapeutics Announces $14 Million Registered Direct Offering

BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia

Mar 3, 2025, 7:00 AM EST - 4 months ago

BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 28, 2025, 7:00 AM EST - 4 months ago

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

BioXcel Therapeutics Announces Reverse Stock Split

Feb 6, 2025, 7:00 AM EST - 5 months ago

BioXcel Therapeutics Announces Reverse Stock Split

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

Nov 22, 2024, 8:16 AM EST - 8 months ago

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

BioXcel Therapeutics Announces Proposed Public Offering

Nov 21, 2024, 4:47 PM EST - 8 months ago

BioXcel Therapeutics Announces Proposed Public Offering

BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 9:07 AM EST - 8 months ago

BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

Nov 8, 2024, 7:00 AM EST - 8 months ago

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

BioXcel Therapeutics to Present at ThinkEquity Conference

Oct 29, 2024, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics to Present at ThinkEquity Conference

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

Oct 15, 2024, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

Sep 19, 2024, 7:00 AM EDT - 10 months ago

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Sep 5, 2024, 7:00 AM EDT - 11 months ago

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 9:48 PM EDT - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript

BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film

Jul 16, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

May 28, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

May 21, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

BioXcel Therapeutics, Inc. (BTAI) Q1 2024 Earnings Call Transcript

May 9, 2024, 9:53 AM EDT - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q1 2024 Earnings Call Transcript

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

May 9, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 25, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

Apr 24, 2024, 10:30 AM EDT - 1 year ago

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

Apr 22, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia

Apr 10, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia

BioXcel Therapeutics Announces $25 Million Registered Direct Offering

Mar 25, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces $25 Million Registered Direct Offering

BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

Mar 15, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

BioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 11:00 AM EDT - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Call Transcript

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

Mar 12, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

Mar 1, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

BioXcel Therapeutics Announces Termination of Proposed Public Offering

Feb 13, 2024, 9:00 AM EST - 1 year ago

BioXcel Therapeutics Announces Termination of Proposed Public Offering

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

Feb 12, 2024, 7:14 AM EST - 1 year ago

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®

Feb 6, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®

BioXcel Therapeutics Announces USPTO's Allowance of Patent Application for Method of Treating Agitation in Alzheimer's Disease Using Oromucosal Formulations of Dexmedetomidine

Feb 5, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces USPTO's Allowance of Patent Application for Method of Treating Agitation in Alzheimer's Disease Using Oromucosal Formulations of Dexmedetomidine

BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today

Dec 12, 2023, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today

BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

Dec 11, 2023, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023

Nov 30, 2023, 7:00 AM EST - 1 year ago

BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023

BioXcel Therapeutics, Inc. (BTAI) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 10:27 AM EST - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q3 2023 Earnings Call Transcript

BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results

Nov 14, 2023, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype

Nov 8, 2023, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype

BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)

Nov 6, 2023, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)

BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023

Oct 31, 2023, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023

BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services

Oct 30, 2023, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services

BioXcel Therapeutics shares pop after audit of Alzheimer's trial data

Oct 25, 2023, 8:44 AM EDT - 1 year ago

BioXcel Therapeutics shares pop after audit of Alzheimer's trial data

BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site

Oct 25, 2023, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site

Hurtadogoalkeeper
Hurtadogoalkeeper Jul. 16 at 8:26 AM
$BTAI https://www.gurufocus.com/news/2978384/btai-bioxcel-therapeutics-receives-steady-buy-rating-from-lucid-capital-markets-btai-stock-news
0 · Reply
Bulltrader988
Bulltrader988 Jul. 16 at 7:19 AM
$BTAI 👃👀 https://www.tipranks.com/news/the-fly/bioxcel-therapeutics-announces-patent-allowance-for-dexmedetomidine-thefly?utm_source=webullapp.com&utm_medium=referral
0 · Reply
Bulltrader988
Bulltrader988 Jul. 16 at 7:19 AM
$BTAI 👃👀 https://www.tipranks.com/news/the-fly/lucid-reiterates-buy-on-bioxcel-after-patent-application-approval-thefly?utm_source=webullapp.com&utm_medium=referral
0 · Reply
NancyBraddy886
NancyBraddy886 Jul. 16 at 5:43 AM
$BTAI Avoiding setups that move too fast
0 · Reply
Thabeastdavis
Thabeastdavis Jul. 15 at 7:20 PM
$BTAI how does this get a $66 price target and it falls??
1 · Reply
Ernesto62
Ernesto62 Jul. 15 at 7:12 PM
$BTAI yep
0 · Reply
jv39
jv39 Jul. 15 at 6:21 PM
$BTAI Fuck this shit
1 · Reply
sn0wball
sn0wball Jul. 15 at 4:27 PM
$BTAI they also say nucana is worth 54$
0 · Reply
_www_larval_com_
_www_larval_com_ Jul. 15 at 4:02 PM
$BTAI has turned -4% lower to 3% (~866Kv) in the last few minutes, 08/15 options, follow for more volatility.
0 · Reply
RJLeonii
RJLeonii Jul. 15 at 2:56 PM
$BTAI PT of $66 🤑
1 · Reply
Albbro
Albbro Jul. 15 at 2:54 PM
$BTAI ?????
0 · Reply
jv39
jv39 Jul. 15 at 2:40 PM
$CYCC news $BTAI news
0 · Reply
silentmaxx
silentmaxx Jul. 15 at 2:24 PM
$BTAI
0 · Reply
JarvisFlow
JarvisFlow Jul. 15 at 1:55 PM
LUCID CAPITAL MARKETS updates rating for BioXcel Therapeutics ( $BTAI ) to Buy, target set at 66.
1 · Reply
Ernesto62
Ernesto62 Jul. 15 at 1:06 PM
$BTAI will drop again
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 15 at 1:05 PM
$BTAI 2 key
0 · Reply
Sibilance
Sibilance Jul. 15 at 12:45 PM
$BTAI https://www.investing.com/news/sec-filings/bioxcel-therapeutics-receives-uspto-allowance-for-new-igalmi-dosing-patent-93CH-4135579
0 · Reply
Sibilance
Sibilance Jul. 15 at 12:40 PM
$BTAI
0 · Reply
HoosierDaddy1728
HoosierDaddy1728 Jul. 11 at 2:30 PM
$DARE Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment Daré is eligible for continued non-dilutive funding installments of up to approximately $11.2 million Market cap $21 million FDA-approved product for the treatment of bacterial vaginosis Treatment for female sexual arousal disorder set to start sales q4 Non hormonal contraceptive in phase 3 $VERU $IFRX $BTAI $OGN
0 · Reply
HummingbirdWhispers
HummingbirdWhispers Jul. 9 at 4:24 PM
$BTAI
0 · Reply
AnnaM7
AnnaM7 Jul. 9 at 3:34 PM
$BTAI Guys, why are we still here? Is there a green light in the end of the tunnel?
1 · Reply
Bulltrader988
Bulltrader988 Jul. 8 at 6:09 PM
$BTAI 👃👀
0 · Reply